Seqirus, a US-based company that deals with influenza prevention and a CSL Limited (ASX:CSL) business, announced on Tuesday that it has received supplemental approval from the United States Food and Drug Administration (FDA) for a multi-dose vial presentation of AUDENZ (Influenza A(H5N1) Monovalent Vaccine, Adjuvanted), the first-ever adjuvanted, cell-based influenza vaccine aimed at protecting individuals six months of age and older against influenza A(H5N1) in the event of a pandemic.
The approval is claimed to represent an important milestone in the company's pandemic preparedness efforts in collaboration with the Biomedical Advanced Research and Development Authority, a component of the Office of the Assistant Secretary for Preparedness and Response within the United States Department of Health and Human Services.
According to the terms of the public-private collaboration, the company is to position itself to deliver 150 million influenza vaccine doses to the United States government to support an influenza pandemic response within six months.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval